 A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL-2 inhibitor venetoclax in model of venetoclax-resistant AML KT-253 also active in other hematologic malignancies including DLBCL WATERTOWN, Mass., Dec. 11, 2022 GLOBE NEWSWIRE Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical ... The post Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253,... 